Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
16 studies found for:    SCH-727965 OR dinaciclib
Show Display Options
Rank Status Study
1 Completed Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Conditions: Solid Tumors;   Lymphoma, Non-Hodgkin;   Multiple Myeloma
Interventions: Drug: SCH 727965;   Drug: Aprepitant;   Drug: Ondansetron;   Drug: Dexamethasone
2 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Pancreatic Acinar Cell Carcinoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Dinaciclib;   Drug: Akt Inhibitor MK2206;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
3 Recruiting Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors
Conditions: Adult Solid Neoplasm;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier
Interventions: Drug: Veliparib;   Drug: Dinaciclib;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
4 Recruiting Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Condition: Refractory Plasma Cell Myeloma
Interventions: Drug: Dinaciclib;   Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis
5 Active, not recruiting Dinaciclib in Treating Patients With Stage III-IV Melanoma
Conditions: Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma
Interventions: Drug: dinaciclib;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Active, not recruiting Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Dinaciclib;   Drug: Epirubicin Hydrochloride;   Other: Laboratory Biomarker Analysis
7 Terminated SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)
Conditions: Lymphoma, Mantle-Cell;   Leukemia, Lymphocytic, Chronic, B-Cell
Interventions: Drug: SCH 727965;   Drug: Bortezomib;   Biological: Alemtuzumab
8 Terminated SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)
Conditions: Leukemia, Myeloid, Acute;   Lymphoblastic Leukemia, Acute
Interventions: Drug: SCH 727965;   Drug: Gemtuzumab ozogamicin
9 Active, not recruiting Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia
Interventions: Biological: Ofatumumab;   Drug: Dinaciclib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
10 Completed SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
Conditions: Breast Neoplasms;   Carcinoma, Non-Small-Cell Lung
Interventions: Drug: SCH 727965;   Drug: Capecitabine;   Drug: Erlotinib
11 Completed A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Dinaciclib;   Biological: Rituximab
12 Completed A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: Dinaciclib;   Drug: Ofatumumab
13 Active, not recruiting Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression
Conditions: Malignant Solid Tumour;   Triple-negative Breast Cancer
Intervention: Drug: Dinaciclib & paclitaxel treatment
14 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
15 Completed
Has Results
Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: dinaciclib;   Other: laboratory biomarker analysis
16 Completed Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
Conditions: Solid Tumors;   Lymphoma, Non-Hodgkin;   Multiple Myeloma;   Leukemia, Lymphocytic, Chronic. B-Cell
Intervention: Drug: SCH 727965

Indicates status has not been verified in more than two years